Respiratory motion-correction for CO2-stress PET imaging

CO2 应激 PET 成像的呼吸运动校正

• 批准号: 463679-2014
• 负责人: deKemp, Robert
• 金额: $ 1.68万
• 依托单位: University of Ottawa
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2014
• 资助国家: 加拿大
• 起止时间: 2014-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=558540
• 关键词: Respiratory; motion; correction; CO2; stress

Vascularix is a wholly-owned subsidiary of Thornhill Scientific lnc., a spin-off of Toronto's University Health Network. We are commercializing the RespirAct system, which controls gas concentrations in the lungs and blood, as a non-invasive, drug-free, stress agent for use in cardiac blood flow testing. Cardiac stress testing is performed to identify patients with heart disease, and to guide treatment. The RespirAct system has been used as a scientific tool for brain vascular assessment in over 500 clinical cases resulting in over 40 peer-reviewed publications primarily based on brain vascular reactivity. Vascularix is pursuing the commercialization of RespirAct for the cardiac stress test indication first, as the expected adoption and reimbursement landscape is more favorable than for the brain indications studied to date.

Vascularix是Thornhill Scientific Inc.的全资子公司，多伦多大学健康网络的一个分支。我们正在将RespirAct系统商业化，该系统控制肺部和血液中的气体浓度，作为一种非侵入性、无药物的压力试剂用于心脏血流测试。进行心脏负荷测试以识别患有心脏病的患者并指导治疗。RespirAct系统已在500多例临床病例中用作脑血管评估的科学工具，产生了40多篇主要基于脑血管反应性的同行评审出版物。Vascularix正在寻求将RespirAct首先用于心脏负荷测试适应症的商业化，因为预期的采用和报销前景比迄今为止研究的大脑适应症更有利。